文献速递心律失常血脂与心血管预防

社区队列中房颤流行病学、危险因素与死亡率的性别差异与相似性:BiomarCaRE 联盟结果

Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe).
PubMed 文献 · Circulation · 2017-10-16

新发房颤者死亡风险为无房颤者的 3.5 倍,BMI 可解释约 20% 的房颤风险。

要点

  • 女性房颤累积发病率低于男性,但终生风险两性均超过 30%。
  • 新发房颤者死亡风险约为无房颤者的 3.5 倍,两性均如此。
  • BMI 与房颤关联存在性别差异,女性 HR 1.18、男性 1.31(交互 P=0.001)。

核心结论

  • 房颤终生风险高,且与死亡风险增加强烈相关,女性和男性均如此。
  • BMI 解释了房颤风险的较大比例,约 20%。
  • BMI 和总胆固醇与房颤的关联存在性别差异,需进一步评估其病理生理及性别特异性预防策略的意义。

研究设计与样本

  • 中位年龄 49.6 岁(范围 24.1-97.6 岁),女性占 51.7%,中位随访 12.6 年(最长 28.2 年)。
  • 分析房颤发病率、其与死亡率的关联、常见危险因素、生物标志物及现患心血管病,并按性别计算归因风险。

主要发现

  • 女性房颤病例 1,796 例(4.4%),男性 2,465 例(6.4%)。
  • 男性基线心血管危险因素分布和血脂谱较女性更不利,心血管病患病率更高。
  • 房颤累积发病率在男性 50 岁后、女性 60 岁后明显增加。
  • 两性终生风险相似(>30%)。
  • 新发房颤者死亡风险为无房颤者的 3.5 倍。

关键数值与推荐

  • BMI 每增加 1 个标准差与房颤的关联:女性 HR 1.18(95%CI 1.12-1.23),男性 HR 1.31(95%CI 1.25-1.38),交互 P=0.001。
  • 总胆固醇每增加 1 个标准差与房颤呈负相关:女性 HR 0.86(95%CI 0.81-0.90),男性 HR 0.92(95%CI 0.88-0.97),交互 P=0.023。
  • C 反应蛋白和 N 末端 B 型利钠肽原与房颤的关联未见性别差异。
  • 所有危险因素合并的人群归因风险:女性 41.9%,男性 46.0%。
  • BMI 的归因风险约为 20%。

临床怎么用

  • 在房颤风险评估和预防中应关注 BMI,尤其需认识其与房颤关联的性别差异。
  • 总胆固醇与房颤的负相关在女性中更明显,性别特异性预防策略需进一步研究。
  • 新发房颤提示死亡风险显著升高,两性均应加强风险管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrial fibrillation (AF) is a common cardiac disease in aging populations with high comorbidity and mortality. Sex differences in AF epidemiology are insufficiently understood. METHODS: In N=79 793 individuals without AF diagnosis at baseline (median age, 49.6 years; age range, 24.1-97.6 years; 51.7% women) from 4 community-based European studies (FINRISK, DanMONICA, Moli-sani Northern Sweden) of the BiomarCaRE consortium (Biomarker for Cardiovascular Risk Assessment in Europe), we examined AF incidence, its association with mortality, common risk factors, biomarkers, and prevalent cardiovascular disease, and their attributable risk by sex. Median follow-up time was 12.6 (to a maximum of 28.2) years. RESULTS: Fewer AF cases were observed in women (N=1796; 4.4%), than in men (N=2465; 6.4%). Cardiovascular risk factor distribution and lipid profile at baseline were less beneficial in men than in women, and cardiovascular disease was more prevalent in men. Cumulative incidence increased markedly after the age of 50 years in men and after 60 years in women. The lifetime risk was similar (>30%) for both sexes. Subjects with incident AF had a 3.5-fold risk of death in comparison with those without AF. Multivariable-adjusted models showed sex differences for the association of body mass index and AF (hazard ratio per standard deviation increase, 1.18; 95% confidence interval [CI], 1.12-1.23 in women versus 1.31; 95% CI 1.25-1.38 in men; interaction P value of 0.001). Total cholesterol was inversely associated with incident AF with a greater risk reduction in women (hazard ratio per SD, 0.86; 95% CI, 0.81-0.90 versus 0.92; 95% CI, 0.88-0.97 in men; interaction P value of 0.023). No sex differences were seen for C-reactive protein and N-terminal pro B-type natriuretic peptide. The population-attributable risk of all risk factors combined was 41.9% in women and 46.0% in men. About 20% of the risk was observed for body mass index. CONCLUSIONS: Lifetime risk of AF was high, and AF was strongly associated with increased mortality both in women and men. Body mass index explained the largest proportion of AF risk. Observed sex differences in the association of body mass index and total cholesterol with AF need to be evaluated for underlying pathophysiology and relevance to sex-specific prevention strategies.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017. PMID: 29038167. doi:10.1161/CIRCULATIONAHA.117.028981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。